Why we built a simpler, lower-cost pathway to Neridronate treatment in Italy and why we believe patients deserve to know this option exists.
There is a moment we have witnessed more than once in the CRPS world.
A patient arrives exhausted.
Not simply from pain, but from everything that has come before it.
The appointments. The medications. The procedures. The nights without sleep. The explanations to family members. The treatments that helped temporarily. The treatments that did nothing. And the constant uncertainty about what to try next.
CRPS patients come to us with tears of pain and return with tears of joy.
That sentence sounds emotional because CRPS is emotional.
But it also needs context.
Neridronate is not a guaranteed cure. Not every patient responds in the same way. Patient experiences are not substitutes for controlled clinical evidence.
But we have seen individual patients regain parts of their lives they thought they had lost.
One returned to hiking.
Another returned to playing the piano.
Others describe changes in pain, movement and everyday independence that matter enormously when CRPS has dictated their lives for months or years.
Their identities remain private. Their experiences are individual, not promises of what will happen to the next patient.
But their stories are part of why CRPS-Neridronate exists.
The question that started everything
Why should accessing Neridronate treatment in Italy require an expensive medical-tourism package?
International CRPS patients were already travelling to Italy.
The medical treatment was here.
The physicians were here.
The Neridronate protocol was here.
Rome was one of the world’s best-connected cities.
Yet international patients could face substantial additional costs when treatment was bundled together with accommodation, transportation, translation, tourism and other services.
We saw an opportunity to simplify the model.
What if patients could pay primarily for the medical pathway they actually came to Italy to receive?
- Let them choose their own flight.
- Let them choose whether they want a hotel, apartment or to stay with family.
- Let them decide how much assistance they need.
- Keep the medical component medically focused.
That became the philosophy behind CRPS-Neridronate in Rome:
No-frills medical access. Transparent costs. Treatment first.
But what exactly is CRPS?
Complex Regional Pain Syndrome is a chronic pain condition that typically develops after an injury, fracture, surgery or other physical trauma.
And calling it simply “pain” doesn’t adequately describe what patients can experience.
CRPS can involve severe disproportionate pain, allodynia, temperature differences, changes in skin colour, swelling, altered sweating, reduced movement and trophic changes affecting areas such as the skin, hair or nails.
Clinicians commonly use the Budapest Criteria when diagnosing the condition.
Those criteria examine four broad areas:
- Sensory.
- Vasomotor.
- Sudomotor/edema.
- Motor/trophic.
That complexity is part of what makes CRPS so difficult to explain and so difficult to treat.
Then there is the bone question
This is where Neridronate becomes scientifically interesting.
Neridronate belongs to a class of medications called bisphosphonates.
Most people associate bisphosphonates with bone diseases rather than chronic pain.
So why have researchers studied them in CRPS?
Bisphosphonates have effects on bone metabolism and osteoclast activity, and several members of this drug class have been investigated in CRPS-I.
The precise relationship between bone metabolism, inflammation and pain in CRPS is complex, and it would be irresponsible to reduce it to a claim that Neridronate simply “repairs the bone” or “fixes the nerves.”
The science is more nuanced than that.
But the clinical research was interesting enough for investigators to study Neridronate specifically.
The Italian protocol
One of the best-known Italian randomized, double-blind, placebo-controlled studies investigated intravenous Neridronate in patients with CRPS-I.
The regimen that became particularly associated with the Italian protocol consisted of:
- 100 mg intravenously per infusion.
- Four infusions.
- Administered over 10 days.
- 400 mg cumulative dose.
That distinction matters because when people talk about “bisphosphonates for CRPS,” they can accidentally treat an entire class of different drugs, doses and routes of administration as though they were interchangeable.
They aren’t.
Neridronate is one specific molecule.
And its clinical development has its own history.
The international story became considerably more complicated
Promising research does not automatically translate into universal regulatory approval.
Later international clinical development of Neridronate produced a more complicated picture, including trials that did not establish the results necessary to move the treatment straightforwardly into widespread use.
That deserves to be said openly.
It is precisely why patients should be suspicious of anyone who presents CRPS treatment as a simple story of:
“This works. Everything else doesn’t.”
Medicine rarely works that way.
- Different study populations matter.
- Trial design matters.
- Disease duration matters.
- Dose matters.
- Endpoints matter.
- Placebo response matters.
And evidence that looks encouraging in one study still needs to survive further testing.
Most interestingly, Neridronate has not disappeared from CRPS research.
It is being investigated again.
A Phase 3 study registered in 2026 is evaluating intravenous Neridronate in adults with CRPS-I.
That raises an important question for patients:
What happens while the research and regulatory process continues?
Patients do not experience CRPS in regulatory timelines
A clinical development program can take years.
A person with CRPS experiences those same years very differently.
- Another year without walking normally.
- Another year away from work.
- Another year unable to tolerate someone touching a hand.
- Another year where playing an instrument, hiking, cooking, driving or simply sleeping normally feels impossibly far away.
This doesn’t mean patients should bypass medical judgment because they’re desperate.
It means they deserve to know what options exist, what evidence supports them, what remains uncertain and what questions they should ask their physicians.
Why we believe Neridronate deserves to be discussed earlier
We are not arguing that every newly diagnosed CRPS patient should immediately fly to Rome.
Nor are we arguing that established CRPS treatments have no role.
CRPS management can involve rehabilitation, medications, psychological support, interventional procedures and neuromodulation depending on the individual patient.
But we do believe that eligible patients should be able to discuss Neridronate with an appropriately qualified physician before automatically assuming that increasingly invasive interventions are their only remaining options.
Neridronate is administered intravenously. It does not require implantation of a device or spinal surgery.
That makes it reasonable, in our view, for appropriately selected patients to ask their medical team where a medically supervised pharmacological option such as Neridronate fits within their individual treatment pathway.
The critical words are appropriately selected.
There are contraindications and medical considerations. A physician must evaluate whether treatment is appropriate.
Why Rome?
Rome gave us an opportunity to rethink the international-patient model.
It has direct connections with major international cities.
Patients have enormous freedom in choosing accommodation.
Public transportation and taxis are readily available.
And, most importantly, we could separate medical treatment from medical tourism.
That distinction became central to what we built.
Some patients want someone to arrange everything.
Others don’t.
Some would rather book their own flight, choose an inexpensive apartment, bring a family member and spend their money on the reason they travelled in the first place:
their treatment.
CRPS-Neridronate was created for the second group.
The stories matter. But the evidence matters more.
Over the years, there have been many patient accounts surrounding Neridronate and CRPS.
We have also encountered powerful individual experiences ourselves.
A patient returning to hiking is meaningful.
Someone returning to the piano is meaningful.
A family watching someone regain independence is meaningful.
But none of those stories proves what will happen to another patient.
That’s why our position is deliberately straightforward:
- Read the research.
- Understand the limitations.
- Confirm the diagnosis.
- Ask about eligibility and contraindications.
- Compare treatment providers and costs.
- Speak with qualified physicians.
Then decide.
CRPS patients have already been promised enough.
They don’t need another miracle story.
They need better information, more transparency and the ability to make informed choices.
The question we want more people asking
The most important question isn’t:
“Does Neridronate cure CRPS?”
That’s too simplistic.
A better question is:
“What does the evidence actually tell us about Neridronate, who might reasonably be considered for it, what remains uncertain, and where should it sit among the treatment options available to someone living with CRPS?”
That is the conversation we want to help create.
And it is why we built a lower-cost, treatment-focused pathway in Rome.
For patients who want to understand the Italian Neridronate protocol, eligibility requirements and what treatment in Rome involves, further information is available through CRPS-Neridronate.
This article is published by CRPS-Neridronate and is intended for educational purposes. We provide access to Neridronate treatment in Rome and therefore have a commercial interest in the treatment discussed above. Patient experiences are individual and do not guarantee outcomes. Medical eligibility and treatment decisions should be assessed by appropriately qualified healthcare professionals.